ClinicalTrials.gg
CompletedNCT02475317Updated Apr 4, 2019

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

A Phase 1 interventional study of Placebo and Maralixibat in Healthy Volunteers, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-04.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Volunteer
03

In context

Lead sponsor

Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. An understanding, ability, and willingness to fully comply with study procedures, study diet, and restrictions.
  2. Ability to voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) /and assent as applicable to participate in the study.
  3. Aged 18-65 years inclusive at the time of consent. The date of signature of the informed consent is defined as the beginning of the screening period. This inclusion criterion will only be assessed at the first screening visit.
  4. Males who agree to comply with any applicable requirements of the protocol or females of non- (see Section 4.4 for details).
  5. Must be considered generally healthy. Health status is defined by the absence of evidence of any active or chronic disease (see Section 7.2.2.1 for details and exceptions) following the completion of a detailed medical and surgical history, a complete physical examination, vital signs, 12-lead , hematology, blood chemistry, and urinalysis.
  6. Must have a of 25.0-35.0 kg/m² inclusive with a body weight >63.5 kg (140 lbs at the first screening visit). This inclusion criterion will only be assessed at the first screening visit.
  7. All clinical laboratory parameters are within normal laboratory limit or not found to be by the principal investigator.
  8. Ability to swallow a dose(s) of product(s).

Exclusion criteria

Exclusion Criteria:

  1. History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological, or psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition of the product, or clinical or laboratory assessments.
  2. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
  3. Known or suspected intolerance or to the investigational product(s), closely-related compounds, or any of the stated ingredients.
  4. Significant illness, as judged by the investigator, within 2 weeks prior to the first dose of investigational product.
  5. Known history of alcohol or other substance abuse within the last year.
  6. Donation of blood or blood products (eg, plasma or ) within 60 days prior to receiving the first dose of investigational product.
  7. Within 30 days prior to the first dose of investigational product:

    • Have used an investigational product (if elimination half-life is \<6 days, otherwise 5 half-lives).
    • Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
    • Have had any substantial changes in eating habits or exercise routine, as assessed by the investigator
  8. Confirmed resting systolic blood pressure >145 mmHg or \<89 mmHg, and diastolic blood pressure >95 mmHg or \<59 mmHg.
  9. Twelve-lead demonstrating >460 milliseconds for male subjects or >470 milliseconds for female subjects at screening. If QTc exceeds 460 milliseconds for males or 470 milliseconds for females, the ECG should be repeated 2 more times and the average of the 3 QTc values should be used to determine the subject's eligibility
  10. A positive screen for drugs of abuse at screening or at Day -3 (check-in).
  11. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit=1 beer or 1 wine [5 oz/150 mL] or 1 liquor [1.5 oz/40 mL] or 0.75 oz alcohol).
  12. A positive , surface antigen (HBsAg), or virus (HCV) antibody screen.
  13. Use of tobacco (eg, smoking or chewing) or other nicotine-containing products (eg, gum, patch) in any form. Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
  14. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz [180 mL] cup of coffee, two 12 oz [360 mL] cans of cola, one 12 oz cup of tea, and three 1 oz [85 g] chocolate bars. Decaffeinated coffee, tea, and cola are not considered to contain caffeine.)
  15. Prior screen failure, randomization, participation, or enrollment in this study. If a subject has successfully completed a study using LUM001 or SHP626, they may participate in this study providing at least 30 days has passed since their last dose of these investigational products and they have successfully completed all screening procedures
  16. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) with the exception of those medications listed in Section 5.2.1. (Current use is defined as use within 14 days of the first dose of investigational product.)
  17. An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.
  18. Colonoscopy, barium enema, or other tests that require a bowel cleansing within 4 weeks prior to the first dose of investigational product.
  19. Subjects who report typically having less than 3 bowel movements per week or greater than 3 bowel movements per day.
  20. Use of antibiotics within 30 days prior to the first dose of investigational product.
  21. Use of bile acid sequestrants within 30 days prior to the first dose of investigational product
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.

    Drug: Placebo

  • Experimental
    Maralixibat 10mg

    Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.

    Drug: Maralixibat

  • Experimental
    Volixibat 10mg

    Participants will receive volixibat 10 mg capsule orally QD for 7 days.

    Drug: Volixibat

  • Experimental
    Maralixibat 20mg

    Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.

    Drug: Maralixibat

  • Experimental
    Volixibat 20mg

    Participants will receive volixibat 20 mg capsule orally QD for 7 days.

    Drug: Volixibat

  • Experimental
    Maralixibat 50mg

    Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.

    Drug: Maralixibat

  • Experimental
    Maralixibat 50mg BID

    Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.

    Drug: Maralixibat

  • Experimental
    Maralixibat 100mg

    Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.

    Drug: Maralixibat

Interventions

  • DrugPlacebo

    Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.

  • Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

    Also known as: LUM001

  • Participants will receive volixibat in 10 mg and 20 mg doses.

    Also known as: SHP626

06

What researchers measure

Primary outcomes

  1. Change From Baseline of Fecal Bile Acid Excretion After Dosing (Day 6 and Day 7)

    Fecal bile acid excretion was determined by the concentration of total bile acids in stool samples over each 24-hour collection window during the lead-in and treatment periods.

    Time frame: Baseline, Day 7

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An AE (classified by preferred term) that occurred during the treatment period was considered a TEAE if it had a start date on or after the first dose of IMP; it had a start date before the date of the first dose of IMP, but increased in severity on or after the date of the first dose of the blinded IMP.

    Time frame: Baseline up to follow-up (up to 16 days)

  2. Change From Baseline in Vital Signs (Supine Pulse Rate and Standing Pulse Rate) at Day 8 / End of Treatment (ET)

    Supine Pulse Rate and Standing Pulse Rate were reported.

    Time frame: Baseline, Day 8

  3. Change From Baseline in Vital Signs (Blood Pressure) at Day 8 / End of Treatment (EOT)

    Supine Systolic Blood Pressure (Supine SBP); Standing Systolic Blood Pressure (Standing SBP); Supine Diastolic Blood Pressure (Supine DBP); Standing Diastolic Blood Pressure (Standing DBP) were reported.

    Time frame: Baseline, Day 8

  4. Change From Baseline in 12-lead Electrocardiogram (ECG) - Heart Rate at Day 8 / End of Treatment (EOT)

    Twelve-lead ECG was performed.

    Time frame: Baseline, Day 8

  5. Change From Baseline in 12-lead ECG Intervals at Day 8

    Twelve-lead ECG was performed. The corrected QT interval (QTc) was derived by Bazett formula (QTcB=QT/(RR)\^1/2) and Fridericia formula (QTcF=QT/(RR)\^1/3). PR Interval; QRS Interval; QT Interval; QTcB Interval; QTcF Interval, RR Intervals were reported.

    Time frame: Baseline, Day 8

  6. Number of Participants with Clinically Meaningful Changes in Serum Biochemistry Laboratory Parameters

    Number of participants with clinically meaningful changes in serum biochemistry laboratory parameters were reported.

    Time frame: Baseline up to Day 8

  7. Number of Participants with Clinically Meaningful Changes in Coagulation and Hematology Parameters

    Activated partial thromboplastin time (aPTT), hematocrit, hemoglobin, monocytes and erythrocytes were analyzed. Number of participants with clinically meaningful change in coagulation and hematology parameters were reported.

    Time frame: Baseline up to Day 8

  8. Number of Participants With Clinically Meaningful Changes in Urinalysis Parameters

    Number of participants with clinically meaningful changes in urinalysis parameters were reported.

    Time frame: Baseline up to Day 8

  9. Change From Baseline in Total Serum Bile Acid Concentration at Day 7

    Serum bile acid concentrations were determined using a validated liquid chromatography with tandem mass spectrometric detection (LC/MS/MS) method.

    Time frame: Baseline, Day 7

  10. Change From Baseline in Serum Concentration of 7- alpha-hydroxy-4-cholesten-3-one (C4) at Day 7

    Serum samples were assayed for C4 using a validated LC/MS/MS method.

    Time frame: Baseline, Day 7

  11. Stool Hardness Measured by Bristol Stool Chart at Day 7

    Stool hardness was assessed according to the Bristol Stool Chart, where 1 was the hardest and 7 was the softest form of stool. Types 3 and 4 were considered normal and types at either end of the scale were considered severe.

    Time frame: Day 7

  12. Frequency of Bowel Movements at Day 7

    Frequency of bowel movements were calculated by treatment group and by day.

    Time frame: Day 7

07

Study locations

1 site
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2015
First posted
Jun 18, 2015
Start
Jun 1, 2015
Primary completionActual
Dec 1, 2015
CompletionActual
Dec 1, 2015
Last update
Apr 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02475317
Responsible party
Sponsor
First posted
Jun 18, 2015
Start date
Jun 1, 2015
Primary completion
Dec 1, 2015
Completion
Dec 1, 2015
Last update
Apr 4, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maralixibat · Volixibat

Start the discussion